What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

Agonist vs Antagonist: Drug Receptor Actions Explained

Name: Agonist vs Antagonist: Drug Receptor Actions Explained
Creator: Dr. Zubair Khalid

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-09-20

An agonist is a ligand that binds a receptor and activates it, producing a measurable tissue response. An antagonist is a ligand that binds the same receptor but has zero intrinsic activity, so it occupies the binding site and prevents agonists from producing their effect.

The agonist vs antagonist distinction is the single most useful idea in clinical pharmacology because it predicts what happens when you change a dose, combine two drugs, or reverse a drug you have already given. A veterinarian who understands agonism and antagonism can explain why atipamezole wakes a xylazine-sedated dog in minutes, why buprenorphine can precipitate withdrawal in a patient on full opioid agonists [1], and why doubling the dose of a partial agonist often does nothing at all [2].

This article is educational and is not a substitute for veterinary diagnosis or treatment.

The Core Vocabulary of Receptor Pharmacology

Four terms carry most of the weight.

Ligand. Any molecule that binds a receptor. A ligand may be an endogenous compound (norepinephrine, acetylcholine, cortisol) or an exogenous drug.

Affinity. How tightly a ligand binds the receptor. High affinity means the drug occupies the receptor at low concentrations.

Intrinsic activity (efficacy). The ability of a bound ligand to activate the receptor and generate a response. Efficacy is a property of the drug-receptor pair, not of binding alone.

Potency. The concentration or dose of drug required to produce a given effect, usually expressed as the half-maximal effective concentration (EC50) or the half-maximal inhibitory concentration (IC50). Potency is a position on the dose axis. Efficacy is a height on the response axis.

Students routinely conflate these last two. A drug can be extremely potent and still produce a small maximal response. A drug can be weakly potent and produce a full maximal response if you give enough of it. Potency tells you where the curve sits. Efficacy tells you how tall the curve gets.

Agonism: Binding That Produces a Response

Agonism is receptor occupation that stabilizes the receptor in its active conformation. The receptor then propagates a signal, whether that signal is a G protein cascade, an ion channel opening, or a change in gene transcription.

Full agonists produce the maximal response the tissue is capable of generating. Endogenous examples include epinephrine at beta-adrenergic receptors and acetylcholine at muscarinic receptors. A veterinary example is xylazine, an alpha-2 adrenergic agonist that produces sedation, muscle relaxation, and analgesia by activating presynaptic and central alpha-2 receptors.

Agonist dose-response curves are typically sigmoidal. At low doses the response rises steeply. As receptors become saturated, the curve flattens into a plateau called the maximal effect, or Emax. Adding more drug beyond that point increases the risk of off-target effects without increasing the desired response.

Agonists can be further classified by where they bind. Orthosteric agonists bind the same site as the endogenous ligand. Allosteric agonists bind a separate site and modulate receptor activity without competing directly. The opioid receptor literature describes agonist-antagonist compounds that produce kappa receptor agonism alongside mu receptor partial agonism or antagonism, and the balance of these actions shifts with dose [2].

Antagonism: Occupying the Receptor Without Activating It

Antagonism is receptor occupation with zero intrinsic activity. The antagonist binds, the receptor stays silent, and any agonist present is physically or functionally excluded from producing its effect.

Pure antagonists have affinity but no efficacy. Examples include atipamezole, a selective alpha-2 adrenergic antagonist used to reverse xylazine and dexmedetomidine sedation in dogs and cats, and naloxone, an opioid receptor antagonist used to reverse opioid overdose.

Antagonists produce no response on their own. Give atipamezole to an unsedated animal and the visible effect is minimal, because there is little alpha-2 agonist tone to block. Give it to a xylazine-sedated animal and arousal is rapid, because you are removing an active agonist drive.

This is the practical heart of the agonist and antagonist relationship. The antagonist does not create an opposite effect. It removes an existing effect.

Competitive Antagonism

A competitive antagonist binds reversibly at the same site as the agonist. The two molecules compete for the same binding pocket. The outcome depends on relative concentrations and relative affinities.

The signature of competitive antagonism is a parallel rightward shift of the agonist dose-response curve with no change in the maximal response. If you add enough agonist, you can outcompete the antagonist and still reach full Emax. The antagonist makes the agonist less potent without making it less efficacious.

A clean experimental demonstration comes from cannabinoid pharmacology. The CB2 antagonist AM630 competitively inhibited the CB2 agonist response to (+)-trans-cannabidiol with a Schild slope of 1.1, which is the expected value for simple competitive antagonism at a single receptor site [3].

Clinically, competitive antagonism is reversible and surmountable. This is why naloxone reversal of opioid sedation can be titrated, and why the effect wears off as the antagonist is cleared.

Noncompetitive Antagonism

A noncompetitive antagonist cannot be overcome by adding more agonist. It may bind irreversibly at the orthosteric site, bind at an allosteric site that prevents activation, or interfere with a step downstream of the receptor.

The signature of noncompetitive antagonism is a depressed maximal response. The dose-response curve does not shift neatly to the right. It flattens. No amount of agonist restores full Emax because a fraction of the receptor pool has been functionally removed.

The distinction matters clinically. If a patient is not responding to an agonist, ask whether the blocker is competitive or noncompetitive. A competitive blocker can be overwhelmed. A noncompetitive blocker cannot.

Partial Agonism: Submaximal Efficacy at Full Occupancy

A partial agonist binds the receptor and activates it, but produces a response that is less than the tissue maximum even when every receptor is occupied.

The mechanism is intrinsic efficacy. Partial agonists stabilize the active receptor conformation less effectively than full agonists. The receptor still signals, just not as loudly.

The clinical consequence is a ceiling effect. Doubling the dose of a partial agonist beyond full receptor occupancy does not increase the response. The ceiling reflects limited intrinsic efficacy, not a dose-dependent conversion of the drug into an antagonist [2]. This is a common misconception and it appears repeatedly in the opioid literature, where mu partial agonists are sometimes mischaracterized as behaving like antagonists at high doses.

Buprenorphine is the classic veterinary and medical example. It is a high-affinity partial mu opioid receptor agonist [1]. Its high affinity means it can displace full agonists from the receptor. Its partial efficacy means the resulting response is lower than what the displaced full agonist was producing. That combination is exactly why transitioning a patient from high-dose methadone to buprenorphine can precipitate withdrawal [1].

Partial agonism also appears in dopamine pharmacology. Cariprazine is a low-efficacy partial agonist at the dopamine D3 receptor, and structural work shows that small positional shifts of the ligand within the binding site separate partial agonists from inverse agonists and full agonists [4]. A D1/D5 receptor partial agonist is under study for cognitive impairment in schizophrenia using a target-engagement design [5]. The antipsychotic dose-response literature notes that partial dopamine agonists behave differently from full antagonists, with at least equal effect sizes on positive and negative symptoms in some analyses [6].

Inverse Agonism: Reducing Constitutive Activity

Some receptors have basal activity even without a ligand. This is called constitutive activity. An inverse agonist binds such a receptor and reduces signaling below the baseline.

An inverse agonist is not the same as an antagonist. A neutral antagonist leaves basal activity unchanged. An inverse agonist actively suppresses it.

Two well-documented examples illustrate the concept. CXCL11 acts as an inverse agonist at the viral G protein-coupled receptor ORF74, which has high basal activity, while CXCL13 acts as an agonist at the same receptor [7]. Primulagenin A is a potent inverse agonist of the nuclear receptor RORγ, with an IC50 of 119 nmol/L and 87% maximal efficacy, and it downregulates RORγ target genes and inhibits Th17 differentiation [8]. A CB2 receptor inverse agonist reduced airway remodeling and corrected Th1/Th2 imbalance in a rat asthma model [9].

Inverse agonism is a real category, not a theoretical curiosity, but it is also the least commonly encountered of the four in day-to-day veterinary practice.

Summary Comparison Table

Property	Full Agonist	Partial Agonist	Neutral Antagonist	Inverse Agonist
Affinity	High	High	High	High
Intrinsic efficacy	Full (100%)	Reduced (greater than 0, less than 100%)	Zero	Negative
Effect alone	Produces response	Produces submaximal response	No response	Reduces basal activity
Dose-response curve	Standard sigmoid reaching Emax	Sigmoid with depressed Emax	Flat alone, shifts agonist curve rightward	Flat alone, shifts basal activity downward
Effect of adding more drug	Response plateaus at Emax	Response plateaus below Emax	No additional effect	No additional effect
Competitive with agonist?	Not applicable	Yes, can compete	Yes if reversible at same site	Varies
Veterinary example	Xylazine (alpha-2 agonist)	Buprenorphine (mu partial agonist)	Atipamezole (alpha-2 antagonist)	CB2 inverse agonist in experimental asthma models [9]

Efficacy vs Potency: The Distinction That Trips Up Exams

Efficacy is the maximal response a drug can produce. Potency is the dose or concentration needed to produce a given response.

Picture two agonists acting on the same receptor. Drug A reaches Emax at 1 mg/kg. Drug B reaches the same Emax at 10 mg/kg. Drug B is less potent. It is not less efficacious. Both produce the same maximal effect, just at different doses.

Now picture Drug C, a partial agonist. It reaches only 60% of Emax no matter how much you give. Drug C is less efficacious than A or B. It may be more potent than both if it reaches its ceiling at a very low dose.

This distinction has direct clinical consequences. If you need a full analgesic effect and you have a partial agonist, increasing the dose will not get you there. You need a different drug or a different approach. The opioid agonist-antagonist literature makes this point explicitly: the analgesic ceiling seen with mu partial agonists reflects limited intrinsic efficacy [2].

Potency also determines practical dosing intervals and safety margins, but it never tells you the ceiling.

How These Actions Are Measured in Practice

Dose-response curves are the standard tool. You plot drug concentration on a logarithmic x-axis and response on the y-axis. The shape of the curve tells you the mechanism.

A parallel rightward shift with unchanged Emax indicates competitive antagonism. A depressed Emax indicates noncompetitive antagonism or partial agonism, depending on whether the drug is given alone or in the presence of a full agonist.

In vitro assays use intracellular calcium mobilization, cAMP accumulation, beta-arrestin recruitment, or membrane potential changes to quantify receptor activation. For example, CXCL13 dose-dependently induced ORF74-mediated calcium release and beta-arrestin recruitment, confirming agonist activity, while CXCL11 showed no agonist activity in the same assays but antagonized the receptor [7]. A fluorescence-based membrane potential assay in AtT20 cells distinguished CB2 agonist activity of (+)-trans-cannabidiol, with a pEC50 of 6.63 and a maximal effect 90% of the reference agonist CP55940 [3].

In vivo, antinociception assays such as the tail-flick test quantify agonist dose-response relationships. The dual MOP/NOP partial agonist AT121 produced dose-dependent antinociception in rats across a range of 0.0025 to 0.02 mg/kg, with the highest dose exceeding morphine's maximal effect and prolonging analgesia to 11 hours versus 6 hours for morphine [10]. Naloxone completely blocked morphine analgesia but only partially attenuated AT121 analgesia, which is consistent with AT121 acting through more than one receptor population [10].

Selectivity matters too. Motugivatrep is a TRPV1 antagonist with IC50 values of 0.46 to 2.1 nM across species, and it showed no significant activity at TRPV3, TRPA1, or TRPM8 [11]. A drug that hits only the intended receptor produces cleaner dose-response data and fewer off-target effects.

Clinical Relevance: Why This Matters at the Cage Side

Every sedation reversal, every opioid rotation, and every "why isn't this drug working" question comes back to agonism and antagonism.

Reversal agents are antagonists. Atipamezole reverses alpha-2 agonists. Naloxone reverses opioids. Flumazenil reverses benzodiazepines. Each works because it displaces or blocks an agonist that is actively driving the clinical effect.

Partial agonists create ceiling effects and can precipitate withdrawal. Buprenorphine's high affinity for the mu receptor means it can displace a full agonist like methadone, and its partial efficacy means the replacement signal is weaker [1]. In patients on high-dose methadone, this can trigger precipitated withdrawal even when a short-acting full agonist bridge is used [1].

Agonist-antagonist compounds occupy a middle ground. The opioid literature describes these drugs as sitting between high-efficacy agonists and pure antagonists, with dose-dependent receptor interactions that produce synergistic or functionally antagonistic effects depending on the dose range and the receptors involved [2].

Dose-response relationships are not always monotonic. The antipsychotic dose-response meta-analysis found that most drugs showed parallel dose-response curves for positive and negative symptoms, but in most cases the curves declined until reaching an inflection point, then plateaued or the efficacy decreased [6]. More drug is not always more effect.

Clinical Relevance, Limitations and Common Mistakes

Mistake 1: Confusing potency with efficacy. A more potent drug is not a stronger drug. It just works at a lower dose. Check Emax before assuming a potent drug will produce a bigger response.

Mistake 2: Assuming a partial agonist will behave like a full agonist if you give enough. It will not. The ceiling is set by intrinsic efficacy, not by dose [2].

Mistake 3: Treating all antagonists as interchangeable. Competitive antagonists can be overcome by agonist. Noncompetitive antagonists cannot. The clinical strategy differs.

Mistake 4: Forgetting that antagonists produce no effect alone. If you give an alpha-2 antagonist to an animal with no alpha-2 agonist on board, you should not expect a dramatic response.

Mistake 5: Overlooking inverse agonism. A drug that reduces constitutive receptor activity is not a neutral antagonist, and its effects may be unexpected if you assume baseline activity is zero.

Mistake 6: Ignoring species differences. Receptor distribution, density, and subtype expression vary across species. A drug that is a potent agonist in one species may be less effective in another.

Individual patients vary in receptor density, concurrent medications, and disease state, so a veterinarian should evaluate each case rather than extrapolating from population data.

Quick Review

Agonist = binds and activates. Antagonist = binds and blocks. Partial agonist = binds and activates partially.
Efficacy is the height of the response. Potency is the dose needed to get there.
Competitive antagonism shifts the agonist curve rightward in parallel. Noncompetitive antagonism depresses the maximum.
Partial agonists have a ceiling effect from limited intrinsic efficacy, not from a switch to antagonism [2].
Inverse agonists reduce constitutive receptor activity below baseline.
Atipamezole reverses xylazine because it is a competitive alpha-2 antagonist.
Buprenorphine is a high-affinity partial mu agonist that can precipitate withdrawal by displacing full agonists [1].

Frequently Asked Questions

What is the difference between an agonist and an antagonist?

An agonist binds a receptor and activates it to produce a response. An antagonist binds the same receptor but produces no activation, blocking the agonist's effect instead.

Can a partial agonist act as an antagonist?

Yes, in the presence of a full agonist. A partial agonist with high affinity can displace a full agonist and produce a lower response, which looks like antagonism even though the drug is activating the receptor.

What does a rightward shift in a dose-response curve mean?

A parallel rightward shift means the agonist has become less potent but can still reach its full maximal effect. This is the hallmark of competitive antagonism.

Why does a noncompetitive antagonist lower the maximum response?

A noncompetitive antagonist removes or disables a fraction of the receptor pool. No amount of agonist can overcome that loss, so the ceiling drops.

Is atipamezole an agonist or antagonist?

Atipamezole is a selective alpha-2 adrenergic antagonist. It reverses sedation produced by alpha-2 agonists such as xylazine and dexmedetomidine.

What is an inverse agonist in simple terms?

An inverse agonist is a drug that binds a receptor with basal activity and reduces that activity below the resting level. It does more than block. It actively suppresses.